Castle Biosciences Launches IPO on NASDAQ, Aims to Raise $64 Million for Dermatologic Cancer Diagnostics

On July 25, 2019, VCBeat (WeChat ID: vcbeat) learned via Business Wire that biotechnology company Castle Biosciences announced its initial public offering, issuing a total of 4 million shares of common stock at a price of $16 per share. The company’s stock began trading on the NASDAQ stock exchange on the same day under the ticker symbol “CSTL.”

It is reported that Castle Biosciences had previously completed 14 rounds of financing, raising a total of $87.5 million. Among these, the company closed a $20 million financing round in May 2017 and a $14 million round in March 2016.

Castle Biosciences, founded in 2008 and headquartered in Texas, USA, is a biotechnology company. The company is dedicated to developing genetic diagnostic and prognostic testing technologies for skin diseases, leveraging its expertise in cancer genomics and data analytics to provide physicians with comprehensive genetic diagnostic information, thereby improving patient treatment outcomes.

Castle Biosciences believes that dermatological treatment plans should not be formulated solely based on clinical symptoms and pathological factors, but should also incorporate individual genomic information to optimize therapeutic strategies. The company’s diagnostic technologies for skin diseases provide tumor-specific genomic information to guide clinical treatment, facilitating physicians’ research into clinical management approaches and helping patients restore skin health.

Castle Biosciences develops biotechnologies based on molecular diagnostics, which are currently primarily used to diagnose cutaneous squamous cell carcinoma (CSCC) and pigmentation-induced lesions. The company’s DecisionDx series of non-invasive tests helps assess the risk level of cancer metastasis or recurrence in patients, assisting physicians in optimizing treatment plans.

Molecular Diagnosis refers to the application of molecular biology methods to detect changes in the structure of genetic material or gene expression patterns within a patient’s body, thereby facilitating pathological diagnosis. This diagnostic approach is a key component of predictive diagnostics, enabling both the diagnosis of individual genetic disorders and prenatal diagnosis. The scope of molecular diagnostic testing encompasses genes encoding various disease-related structural proteins, enzymes, antigens, antibodies, and immune regulatory molecules.

Castle Biosciences also boasts an experienced R&D team. Its Chief Medical Officer, Dr. Federico Monzon, is a Professor of Molecular Pathology and Immunology, while Bob Cook, Vice President of Research and Development, is an expert in biochemistry, molecular biology, and cell biology.

Castle Biosciences’ clinical laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), and its genomic testing protocols have been individually approved by the New York State Department of Health.

Derek Maetzold, founder of Castle Biosciences, stated, “Emerging molecular biology technologies can improve treatment outcomes for patients with skin cancer. We will continue to focus our R&D efforts and resources on the development of the DecisionDx molecular diagnostic platform, believing that this technology can effectively enhance the diagnosis of skin diseases.”

(Compiled by Xu Xiaoxue)